- Home
- EBS vs RGNX Comparison
EBS vs RGNX Comparison
Compare EBS & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- RGNX
- Stock Information
- Founded
- EBS 1998
- RGNX 2008
- Country
- EBS United States
- RGNX United States
- Employees
- EBS N/A
- RGNX N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EBS Health Care
- RGNX Health Care
- Exchange
- EBS Nasdaq
- RGNX Nasdaq
- Market Cap
- EBS 393.9M
- RGNX 387.0M
- IPO Year
- EBS 2006
- RGNX 2015
- Fundamental
- Price
- EBS $6.34
- RGNX $10.08
- Analyst Decision
- EBS Strong Buy
- RGNX Strong Buy
- Analyst Count
- EBS 3
- RGNX 8
- Target Price
- EBS $14.33
- RGNX $31.75
- AVG Volume (30 Days)
- EBS 1.4M
- RGNX 1.3M
- Earning Date
- EBS 05-07-2025
- RGNX 07-31-2025
- Dividend Yield
- EBS N/A
- RGNX N/A
- EPS Growth
- EBS N/A
- RGNX N/A
- EPS
- EBS N/A
- RGNX N/A
- Revenue
- EBS $965,400,000.00
- RGNX $156,718,000.00
- Revenue This Year
- EBS N/A
- RGNX $313.52
- Revenue Next Year
- EBS $16.07
- RGNX N/A
- P/E Ratio
- EBS N/A
- RGNX N/A
- Revenue Growth
- EBS N/A
- RGNX 80.70
- 52 Week Low
- EBS $4.02
- RGNX $5.04
- 52 Week High
- EBS $15.10
- RGNX $15.36
- Technical
- Relative Strength Index (RSI)
- EBS 55.56
- RGNX 59.83
- Support Level
- EBS $6.20
- RGNX $8.22
- Resistance Level
- EBS $6.68
- RGNX $11.00
- Average True Range (ATR)
- EBS 0.38
- RGNX 0.89
- MACD
- EBS -0.03
- RGNX 0.05
- Stochastic Oscillator
- EBS 59.94
- RGNX 72.29
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.